A PYMNTS Company

US: Teva offers antitrust concessions for $4 billion generics deal

By  |  February 21, 2016

Teva Pharmaceutical Industries has offered concessions to allay antitrust concerns over its $40.5 billion bid for Allergan’s generics unit, European Union regulators said on Friday.

“Commitments have been submitted and the new legal deadline is set on 10 March,” European Commission spokesman Ricardo Cardoso said in an email, without providing details.

Acquiring the Actavis generic business would strengthen Teva’s position as the world’s largest generics drugmaker. The company was not immediately available for comment.

Teva plans to sell about $1 billion worth of assets in the United States, Europe and the Middle East to resolve antitrust concerns, people familiar with the matter have told Reuters. The deal also needs US regulatory approval.

Full Content: Reuters

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.